GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction
Journal of Reconstructive Microsurgery · 05.05.2026
DOI: 10.1055/a-2858-3774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Reconstructive Microsurgery, erschienen am 05.05.2026. Verfasst von Joy Ha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1s) are increasingly used for glycemic control and weight loss, but their impact on surgical wound complications remains unclear. Some studies suggest GLP-1s reduce complications such as infection and dehiscence, while others report increased risk in certain procedures. This study evaluates whether preoperative GLP-1 use is associated with postoperative wound complications in free flap breast reconstruction. We conducted a retrospective cohort study using the TriNetX Research Network, a global database of de-identified health records. Adults (≥18 years) undergoing free flap breast reconstruction (2012–2025) were identified with CPT codes. Patients were stratified into cohorts by GLP-1 use within 1 year before surgery. Prescriptions for semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide defined GLP-1 users. Cohorts underwent 1:1 propensity score matching, and matched groups were analyzed for wound outcomes. Subgroup analyses were performed by diabetes status. In the pooled cohort, GLP-1 users had significantly lower composite wound complication rates compared with non-users (9.0% versus 17.1%, p = 0.002), including reduced surgical site infections (4.1% versus 8.1%, p = 0.026) and wound dehiscence (3.8% versus 7.8%, p = 0.023). No differences were observed in debridement, seroma, or hematoma rates. In subgroup analyses, GLP-1 use was associated with significantly lower composite wound complications in the non-diabetic subgroup (7.9 versus 18.6%, p = 0.007), while overall complication rates in the diabetic subgroup were comparable between users and non-users. Preoperative GLP-1 use was not linked to increased wound complications and may confer benefit, supporting safety when used perioperatively.
Autor:innen und Institutionen
- Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, United States.
ORCID-Profile: Sydney Somers
Zitieren
APA
Ha, J., Lester, E. R., De May, H., Somers, S., Eddington, D., Agarwal, J. P., & Kwok, A. C. (2026). GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction. Journal of Reconstructive Microsurgery. https://doi.org/10.1055/a-2858-3774
Vancouver
Ha J, Lester ER, De May H, Somers S, Eddington D, Agarwal JP, et al. GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction. Journal of Reconstructive Microsurgery. 2026. doi:10.1055/a-2858-3774
BibTeX
@article{Ha2026,
author = {Ha, Joy and Lester, Ethan R and De May, Henning and Somers, Sydney and Eddington, Devin and Agarwal, Jayant P and Kwok, Alvin C},
title = {GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction},
journal = {Journal of Reconstructive Microsurgery},
year = {2026},
doi = {10.1055/a-2858-3774}
}
EUVIMED